1st Patient Dosed in Phase 3 Trial of Batoclimab in China

1st Patient Dosed in Phase 3 Trial of Batoclimab in China

307476

1st Patient Dosed in Phase 3 Trial of Batoclimab in China

The first participant has been dosed in a Phase 3 clinical trial testing the efficacy and safety of batoclimab (HBM9161) in people with generalized myasthenia gravis (gMG) in China. “The first patient first dosing in the phase III study brings us one step closer to deliver the novel therapeutic and we look forward to receiving more evidence soon to support batoclimab as the promising potential novel treatment for gMG patients,” Jingsong Wang, MD, PhD, said…

You must be logged in to read/download the full post.